1. Catalog
  2. Networks
  3. Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications v1.0.0

Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications 1.0.0

Compilation Biogrammar
Explore Query

Provenance

Upload
charles.hoyt@scai.fraunhofer.de at 2019-02-27 16:20:49.564335
Authors
Rana Aldisi
Contact
charles.hoyt@scai.fraunhofer.de
License
CC BY 4.0
Copyright
Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved
Number Nodes
176
Number Edges
307
Number Components
3
Network Density
0.00996753246753247
Average Degree
1.74431818181818
Number Citations
1
Number BEL Errors
0

Content Statistics

Network Overlap

The node-based overlap between this network and other networks is calculated as the Szymkiewicz-Simpson coefficient of their respective nodes. Up to the top 10 are shown below.

Network Overlap
Interplay of neurotransmitters in Alzheimer's disease v1.0.0 25%
The Nicotinic Acetylcholine Receptor: The Founding Father of the Pentameric Ligand-gated Ion Channel Superfamily v1.0.1 24%
Chronic Anatabine Treatment Reduces Alzheimer ’ s Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD v1.0.0 20%
Identification of a novel aspartic protease (Asp 2) as beta-secretase v1.0.0 20%
Effects of peptides derived from BACE1 catalytic domain on APP processing v1.0.0 20%
Alzheimer's Disease: Targeting the Cholinergic System v1.0.0 19%
NACHO Mediates Nicotinic Acetylcholine Receptor Function throughout the Brain v1.0.0 19%
Analysis of Isoform-specific Tau Aggregates Suggests a Common Toxic Mechanism Involving Similar Pathological Conformations and Axonal Transport Inhibition v1.0.1 18%
Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro v1.0.0 18%
Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-b peptide and s levels: target engagement, tolerability and pharmacokinetics in humans v0.1.0 18%

Sample Edges

p(HGNC:MAPT) hasVariant p(HGNC:MAPT, pmod(Ph)) View Subject | View Object

complex(a(CHEBI:"amyloid-beta"), p(HGNC:CHRNA7)) hasComponent a(CHEBI:"amyloid-beta") View Subject | View Object

complex(a(CHEBI:"amyloid-beta"), p(HGNC:CHRNA7)) hasComponent p(HGNC:CHRNA7) View Subject | View Object

a(CHEBI:donepezil) increases act(a(MESH:D005625)) View Subject | View Object

A recent functional MRI study demonstrated that people with MCI treated with the FDA-approved anticholinesterase donepezil demonstrated increased frontal cortex activation relative to untreated controls, which was positively correlated with task performance [31]. PubMed:18986241

Annotations
MeSH
Cognitive Dysfunction

a(CHEBI:physostigmine) decreases path(MESH:D000544) View Subject | View Object

Notably, reports that physostigmine and oral anticholinesterases have beneficial effects for patients with AD suggest that the CBF system is somewhat preserved during the progression of dementia, despite well-documented loss of cholinergic biosynthetic machinery (including ChAT and AChE enzyme deficits) in patients with this disease. Interestingly, recent studies have shown that ChAT activity, which results in acetylcholine (ACh) synthesis, is preserved in the neocortex of people with MCI [18,19]. PubMed:18986241

Annotations
Disease Ontology (DO)
Alzheimer's disease

Sample Nodes

a(CHEBI:"amyloid-beta")

In-Edges: 423 | Out-Edges: 245 | Children: 5 | Explore Neighborhood | Download JSON

p(HGNC:APP)

In-Edges: 106 | Out-Edges: 69 | Explore Neighborhood | Download JSON

p(HGNC:BACE1)

In-Edges: 65 | Out-Edges: 39 | Explore Neighborhood | Download JSON

p(HGNC:MAPT)

In-Edges: 477 | Out-Edges: 480 | Classes: 11 | Children: 27 | Explore Neighborhood | Download JSON

p(HGNC:MAPT, pmod(Ph))

In-Edges: 201 | Out-Edges: 71 | Classes: 1 | Children: 4 | Explore Neighborhood | Download JSON

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.